{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:17:20Z","timestamp":1792588640114,"version":"4.5.0"},"reference-count":20,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2023,8,7]]},"DOI":"10.18632\/oncotarget.28473","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T10:49:21Z","timestamp":1689850161000},"page":"749-752","source":"Crossref","is-referenced-by-count":13,"title":["CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies"],"prefix":"10.18632","volume":"14","author":[{"given":"Daniel","family":"Morillo","sequence":"first","affiliation":[{"name":"Division of Hematology, START Madrid-FJD, Hospital Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gala","family":"Vega","sequence":"additional","affiliation":[{"name":"Division of Hematology, START Madrid-FJD, Hospital Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Moreno","sequence":"additional","affiliation":[{"name":"Division of Oncology, START Madrid-FJD, Hospital Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2023,8,7]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1242\/dev.091744","article-title":"Cdks, cyclins and CKIs: roles beyond cell cycle regulation","volume":"14","author":"Kaldis","year":"2013","journal-title":"Development"},{"key":"2","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1039\/d2md00040g","article-title":"CDK9 inhibitors in cancer research","volume":"1","author":"Fan","year":"2022","journal-title":"RSC Med Chem"},{"key":"3","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.3390\/cancers13092181","article-title":"Targeting CDK9 for Anti-Cancer Therapeutics","volume":"1","author":"Strebhardt","year":"2021","journal-title":"Cancers (Basel)"},{"key":"4","doi-asserted-by":"publisher","first-page":"678559","DOI":"10.3389\/fonc.2021.678559","article-title":"CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents","volume":"1","author":"Albrecht","year":"2021","journal-title":"Front Oncol"},{"key":"5","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/leu.2015.10","article-title":"CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma","volume":"2","author":"Shortt","year":"2015","journal-title":"Leukemia"},{"key":"6","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.leukres.2015.10.010","article-title":"Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia","volume":"3","author":"Karp","year":"2015","journal-title":"Leuk Res"},{"key":"7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/1479-5876-11-259","article-title":"A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies","volume":"1","author":"Bannerji","year":"2013","journal-title":"J Transl Med"},{"key":"8","unstructured":"Bayer Clinical Trials. 16520-phase I dose escalation of BAY1143572 in subjects with acute leukemia. https:\/\/clinicaltrials.bayer.com\/."},{"key":"9","unstructured":"Bayer Clinical Trials. 16519-open label phase I dose escalation study with BAY1143572 in patients with advanced cancer. https:\/\/clinicaltrials.bayer.com."},{"key":"10","doi-asserted-by":"publisher","first-page":"11651","DOI":"10.1021\/acs.jmedchem.1c01000","article-title":"Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer","volume":"6","author":"Mumberg","year":"2021","journal-title":"J Med Chem"},{"key":"11","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1158\/1078-0432.CCR-21-3617","article-title":"First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy","volume":"2","author":"Hamdy","year":"2022","journal-title":"Clin Cancer Res"},{"key":"12","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"12","author":"Vardiman","year":"2016","journal-title":"Blood"},{"key":"13","first-page":"30","article-title":"Real-world data of high-grade lymphoma patients treated with CD19 CAR-T in the UK","volume":"18","author":"Besley","year":"2020","journal-title":"Br J Haematol"},{"key":"14","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"38","author":"Hertzberg","year":"2022","journal-title":"N Engl J Med"},{"key":"15","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"2","author":"Weirather","year":"2020","journal-title":"Lancet Oncol"},{"key":"16","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"2","author":"Feingold","year":"2021","journal-title":"Lancet Oncol"},{"key":"17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"3","author":"Paulson","year":"2020","journal-title":"J Clin Oncol"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100001","article-title":"Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers","volume":"1","author":"Jessen","year":"2022","journal-title":"NEJM Evidence"},{"key":"19","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.3324\/haematol.2021.278654","article-title":"Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study","volume":"10","author":"Dyer","year":"2021","journal-title":"Haematologica"},{"key":"20","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1038\/s41375-022-01553-w","article-title":"Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells","volume":"3","author":"Plunkett","year":"2022","journal-title":"Leukemia"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28473","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T13:34:17Z","timestamp":1691415257000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,7]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,8,7]]}},"alternative-id":["28473"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28473","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,7]]}}}